Hongbin Shi1, Jiangsong Li2, Kui Li3, Xiaobo Yang1, Zaisheng Zhu4, Daxue Tian4. 1. Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. 2. Department of Urology, Liaocheng People's Hospital, Liaocheng, Shandong, China. 3. Department of Urology Surgery, The People's Hospital of Yucheng, Yucheng, China. 4. Department of Urology, Jinhua Hospital, Zhejiang University School of Medicine, Zhejiang, China.
Bladder cancer (BCa) is a common malignancy worldwide that is associated with age and
smoking and that seriously affects the health of the advanced-age population.[1] BCa is also the most common urological malignancy in China, where it has a
high incidence and recurrence rate; among individuals aged >75 years, the
incidence is 69.7/100,000 population.[2] For patients with muscle-invasive BCa or high-risk non-muscle-invasive BCa,
open radical cystectomy (ORC) is the gold standard surgical treatment.[3] With the development of surgical techniques, minimally invasive radical
cystectomy (MIRC) has become more widely used in recent years. MIRC techniques
include laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy
(RARC), both of which are associated with lower morbidity than conventional
surgery.[4,5]
Many studies have compared the advantages and disadvantages between MIRC (LRC or
RARC) and ORC.[6-15] For example, Tang K et al.[14] performed a meta-analysis and found that RARC seems to be a safer and less
invasive treatment than ORC. Tang JQ et al.[15] also performed a meta-analysis that suggested that RARC is a more minimally
invasive treatment than ORC for BCa and has the advantage of reducing bleeding.
However, these meta-analyses lacked enough randomized controlled trials (RCTs) to
prove their findings. In recent years, increasingly more RCTs have been performed to
compare MIRC and ORC in terms of oncologic, perioperative, and pathologic variables
and complications. Therefore, the aim of our meta-analysis was to evaluate the
efficacy and safety of MIRC and ORC in the treatment of BCa.
Materials and methods
Search strategy
We searched the EMBASE and MEDLINE databases to identify all RCTs that focused on
the use of MIRC and ORC in the treatment of BCa. We also searched the references
of the retrieved articles. The following search terms were used: “open radical
cystectomy,” “laparoscopic radical cystectomy,” “robot-assisted radical
cystectomy,” and “randomized controlled trials.”
Inclusion criteria and trial selection
All identified articles were screened by two independent reviewers, and a third
reviewer was involved if there was a discrepancy. The inclusion criteria for
RCTs were as follows: (i) The study included MIRC and ORC for the treatment of
BCa; (ii) accurate data were available and could be analyzed, including the
total number of patients and the values of each index; and (iii) the full text
of the included study was available. When the same study was published in
different journals or years, the most recent publication was used for the
meta-analysis. If the same group of researchers conducted multiple experiments
on a group of patients, each study was included. A flow chart of the selection
process is shown in Figure
1.
Figure 1.
Flow diagram of the study selection process. RCT, randomized controlled
trial.
Flow diagram of the study selection process. RCT, randomized controlled
trial.
Quality assessment
The methodological quality of each RCT was assessed in terms of the means of
patient allocation to various arms of the study, allocation concealment,
blinding, and loss to follow-up. Additionally, the methodological quality of
each cohort study was assessed in terms of the means of patient allocation to
various arms of the study, exposure variables and covariates, sample size
calculation, and propensity score matching. The patients were then classified
qualitatively according to the guidelines published in the Cochrane Handbook for
Systematic Reviews of Interventions 5.1.0.[16] According to the quality evaluation standard, each study was evaluated
using one of the following quality categories: A, quality criteria were met
adequately, and the study was deemed to have a “low” risk of bias; B, quality
criteria were met only partially or were unclear, and the study was deemed to
have a “moderate” risk of bias; and C, quality criteria were not met or not
included, and the study was deemed to have a “high” risk of bias. Differences
were resolved by discussion among the reviewers.
Data extraction
Data included in the study were extracted and cross-checked by two reviewers. Any
differences were settled through discussion or by a third person. The following
information was collected from reports of the original experiment: the name of
the first author and the publication year, country in which the study was
carried out, study design, participants’ age, number of participants, follow-up
duration, surgical approach, and outcome measures. The main outcome was
oncologic outcomes, and the secondary outcomes were perioperative and pathologic
variables and complications.
Statistical analysis and meta-analysis
The meta-analysis was conducted using Review Manager (RevMan) 5.1.0 (The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The
meta-analysis revealed no evidence of publication bias according to the results
of a funnel plot. Continuous variables are presented as the mean difference (MD)
with 95% confidence interval (CI). The odds ratio (OR) with 95% CI was computed
for all dichotomous variables. A fixed-effects model was used if there was no
conspicuous heterogeneity; otherwise, a random-effects statistical model was
used. Tests for heterogeneity were conducted using the I2 statistic
with the level of significance set at P < 0.05. Funnel plots were used to
assess publication bias. Tests of the lowest quality were excluded. The
individual outcome evaluation was performed using the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines, and
the quality of individual outcomes was divided into four grades as follows:
high, medium, low, and very low.
Ethics
Ethics approval was not necessary because all included studies had already
obtained ethical approval from relevant institutions.
Results
Characteristics of the individual studies
Our database search revealed 215 articles that could have been included in our
meta-analysis. After reading the title and abstract of each article and applying
the inclusion and exclusion criteria, 194 articles were excluded. Thirteen
articles lacked useful data and were not RCTs. Finally, eight articles reporting
data from a total of nine RCTs (803 patients)[17-24] were included in the
meta-analysis: six RCTs compared RARC with ORC, and three RCTs compared LRC with
ORC. The baseline characteristics of the studies included in our meta-analysis
are listed in Table
1.
Table 1.
Main characteristic and quality assessment of eligible studies.
Study
Country
Surgical approach in experimental group
Surgical approach in control group
Median age (years)
No. of patients
Type of study
Follow-up (months)
Quality assessment*
Experimental
Control
Experimental
Control
Nix et al., 2010
USA
RARC
ORC
69.2
67.4
21
20
Prospective RCT
9
A
Parekh et al., 2013
USA
RARC
ORC
69.5
64.5
20
20
Prospective RCT
3, 6, 9, 12
A
Lin et al., 2014
China
LRC
ORC
63.2
63.6
35
35
Prospective RCT
26 (LRC),32 (ORC)
A
Bochner et al., 2015
USA
RARC
ORC
66
65
60
58
Prospective RCT
36
A
Khan et al., 2016 A
UK
RARC
ORC
68.6
66.6
20
20
Prospective RCT
40
A
Khan et al., 2016 B
LRC
68.6
19
Yong et al., 2017
China
LRC
ORC
78
77
29
28
Prospective RCT
28
A
Bochner et al., 2018
USA
RARC
ORC
66
65
60
58
Prospective RCT
36
A
Parekh et al., 2018
USA
RARC
ORC
70
67
150
152
Prospective RCT
3, 6, 12,24, and 36
A
RARC, robot-assisted radical cystectomy; ORC, open radical
cystectomy; LRC, laparoscopic radical cystectomy; RCT, randomized
controlled trial; NA, data not available.
*Grade A: if all quality criteria were adequately met, the study was
deemed to have a low risk of bias.
Main characteristic and quality assessment of eligible studies.RARC, robot-assisted radical cystectomy; ORC, open radical
cystectomy; LRC, laparoscopic radical cystectomy; RCT, randomized
controlled trial; NA, data not available.*Grade A: if all quality criteria were adequately met, the study was
deemed to have a low risk of bias.
Quality of the individual studies
All nine RCTs were double-blinded, and all described the randomization processes
that they had used. All included a power calculation to determine the optimal
sample size. Each study was of quality level A (Table 1). A funnel plot was used to
qualitatively estimate publication bias, and no evidence of bias was found
(Figure 2). The risk
of bias of the individual studies is shown in Table 2.
Figure 2.
Funnel plot of the studies represented in this meta-analysis. OR, odds
ratio; SE, standard error; RARC, robot-assisted radical cystectomy; ORC,
open radical cystectomy; LRC, laparoscopic radical cystectomy.
Table 2.
Risk of bias of individual studies.
Study
Sequence generation
Allocation concealment
Blinding
Incomplete outcome data
Selective outcome reporting
Other sources of bias
Nix et al., 2010
+
+
−
+
−
+
Parekh et al., 2013
+
+
−
+
+
?
Lin et al., 2014
+
+
?
+
−
?
Bochner et al., 2015
+
+
−
+
+
+
Khan et al., 2016
+
+
?
+
+
+
Yong et al., 2017
+
+
?
+
+
?
Bochner et al., 2018
+
+
−
+
+
+
Parekh et al., 2018
+
+
−
+
?
+
+, low risk of bias; ?, unclear risk of bias; −, high risk of
bias.
Funnel plot of the studies represented in this meta-analysis. OR, odds
ratio; SE, standard error; RARC, robot-assisted radical cystectomy; ORC,
open radical cystectomy; LRC, laparoscopic radical cystectomy.Risk of bias of individual studies.+, low risk of bias; ?, unclear risk of bias; −, high risk of
bias.
Outcomes of oncologic variables
Recurrence rate and mortality
Five RCTs involving 565 patients (282 in the MIRC group and 283 in the ORC
group) included data on the recurrence rate. We found no heterogeneity among
the studies, and we used the OR to express the effect size for the
meta-analysis. The pooled estimate of OR was 0.95 (95% CI, 0.66–1.37) (Figure 3). Five RCTs
involving 553 patients (277 in the MIRC group and 276 in the ORC group)
included data on mortality. We found no heterogeneity among the studies, and
we used the OR to express the effect size for the meta-analysis. The pooled
estimate of OR was 0.91 (95% CI, 0.60–1.37) (Figure 4). These results suggest that
there was no significant difference in the postoperative recurrence rate or
mortality between MIRC and ORC.
Figure 3.
Forest plots showing the outcome of the recurrence rate. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Figure 4.
Forest plots showing the outcome of mortality. M-H, Mantel–Haenszel;
CI, confidence interval; df, degrees of freedom.
Forest plots showing the outcome of the recurrence rate. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.Forest plots showing the outcome of mortality. M-H, Mantel–Haenszel;
CI, confidence interval; df, degrees of freedom.
Outcome of pathologic variables
Lymph node yield, positive lymph nodes, and positive surgical
margins
Eight RCTs involving 706 patients (354 in the MIRC group and 352 in the
ORC group) included data on the lymph node yield. The pooled estimate of
MD was −1.43 (95% CI, −3.75–0.89) (Figure 5).
Figure 5.
Forest plots showing the outcome of the lymph node yield. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Forest plots showing the outcome of the lymph node yield. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.Four RCTs involving 284 patients (144 in the MIRC group and 140 in the
ORC group) included data on positive lymph nodes. The pooled estimate of
MD was 0.97 (95% CI, 0.53–1.75) (Figure 6).
Figure 6.
Forest plots showing the outcome of positive lymph nodes. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Forest plots showing the outcome of positive lymph nodes. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.Eight RCTs involving 708 patients (354 in the MIRC group and 354 in the
ORC group) included data on the positive surgical margins. The pooled
estimate of MD was 1.00 (95% CI, 0.50–2.03) (Figure 7). These results suggest
that there were no significant differences in the lymph node yield,
positive lymph nodes, or positive surgical margins between MIRC and
ORC.
Figure 7.
Forest plots showing the outcome of positive surgical margins.
M-H, Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Forest plots showing the outcome of positive surgical margins.
M-H, Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Outcomes of perioperative variables
Operating time, estimated blood loss, blood transfusion rate, time to
regular diet, and length of hospital stay
Eight RCTs involving 706 patients (354 in the MIRC group and 352 in the
ORC group) included data on the operating time. The pooled estimate of
MD was 62.90, (95% CI, 36.02–89.78; P < 0.00001) (Figure 8). Eight
RCTs involving 706 participants (354 in the MIRC group and 352 in the
ORC group) included data on the estimated blood loss. The pooled
estimate of MD was −338.78 (95% CI, −422.22 to −255.33; P < 0.00001)
(Figure 9).
Four RCTs involving 468 patients (234 in the MIRC group and 234 in the
ORC group) included data on the blood transfusion rate. The pooled
estimate of OR was 0.46 (95% CI, 0.30–0.70; P = 0.0002) (Figure 10). Six
RCTs involving 286 patients (144 in the MIRC group and 142 in the ORC
group) included data on the time to regular diet. The pooled estimate of
MD was −0.70 (95% CI, −0.93 to −0.46; P < 0.00001) (Figure 11). Eight
RCTs involving 705 patients (354 in the MIRC group and 351 in the ORC
group) included data on the length of hospital stay. The pooled estimate
of MD was −0.93 (95% CI, −1.32 to −0.54; P < 0.00001) (Figure 12). These
results suggest that MIRC had a significantly longer operating time,
less blood loss, lower blood transfusion rate, shorter time to regular
diet, and shorter length of hospital stay than ORC.
Figure 8.
Forest plots showing the outcome of the operating time. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Figure 9.
Forest plots showing the outcome of estimated blood loss. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Figure 10.
Forest plots showing the outcome of the blood transfusion rate.
M-H, Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Figure 11.
Forest plots showing the outcome of the time to regular diet. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Figure 12.
Forest plots showing the outcome of the length of hospital stay.
SD, standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Forest plots showing the outcome of the operating time. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.Forest plots showing the outcome of estimated blood loss. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.Forest plots showing the outcome of the blood transfusion rate.
M-H, Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.Forest plots showing the outcome of the time to regular diet. SD,
standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.Forest plots showing the outcome of the length of hospital stay.
SD, standard deviation; IV, inverse variance; CI, confidence
interval; df, degrees of freedom.
Outcomes of complications
Eight RCTs involving 707 patients (354 in the MIRC group and 353 in the ORC
group) included data on the complication rate. We found no heterogeneity
among the studies, and we used the OR to express the effect size for the
meta-analysis. The pooled estimate of OR was 0.75 (95% CI, 0.54–1.03;
P = 0.07) (Figure
13). This result suggests that the complication rate was similar
between MIRC and ORC.
Figure 13.
Forest plots showing the outcome of the complication rate. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Forest plots showing the outcome of the complication rate. M-H,
Mantel–Haenszel; CI, confidence interval; df, degrees of
freedom.
Subgroup analysis and GRADE assessment of individual outcomes
The surgical approaches in the MIRC group were RARC and LRC (Table 1). We therefore
divided the included studies into two groups: RARC and LRC. Again, we conducted
subgroup analyses for the outcomes of oncologic, perioperative, pathologic and
variables and complications (Figures 3–13). We found no statistically
significant difference in the recurrence rate (I2 = 0%), mortality
(I2 = 0%), lymph node yield (I2 = 0%), positive lymph
nodes (I2 = 0%), positive surgical margins (I2 = 0%),
operating time (I2 = 0%), estimated blood loss
(I2 = 6.3%), blood transfusion rate (I2 = 14%), time to
regular diet (I2 = 0.3%), or length of hospital stay
(I2 = 0%) between RARC versus ORC or LRC versus ORC. The data
suggested that the LRC group had fewer complications than the ORC group (OR,
0.5; P = 0.03). However, the performance of RARC did not significantly reduce
the complications compared with ORC (OR, 0.86). The results of the GRADE
assessment of individual outcomes are shown in Table 3.
Table 3.
GRADE assessment of individual outcomes.
Outcomes
RARC vs. ORC
LRC vs. ORC
GRADE
No. of trials
MD/OR
P value
No. of trials
MD/OR
P value
Recurrence rate
3
0.94
0.76
2
1.02
0.97
Low
Mortality
3
0.87
0.54
2
1.14
0.81
Low
Lymph node yield
5
−2.41
0.2
3
−0.08
0.95
Medium
Positive lymph nodes
2
1.04
0.92
2
0.89
0.8
Low
Positive surgical margins
5
1.16
0.7
3
0.42
0.39
Medium
Operating time
5
70.84
0.0002
3
50.27
0.02
Medium
Estimated blood loss
5
−307.52
<0.00001
3
−391.09
<0.00001
Medium
Blood transfusion rate
2
0.52
0.007
2
0.30
0.008
Low
Time to regular diet
3
−0.96
0.0007
3
−0.64
<0.00001
Low
Length of hospital stay
5
−0.87
<0.00001
3
−1.38
0.02
Medium
Complication rate
5
0.86
0.41
3
0.5
0.03
Medium
GRADE, Grading of Recommendations Assessment, Development, and
Evaluation; OR, odds ratio; MD, mean difference; RARC,
robot-assisted radical cystectomy; ORC, open radical cystectomy;
LRC, laparoscopic radical cystectomy.
GRADE assessment of individual outcomes.GRADE, Grading of Recommendations Assessment, Development, and
Evaluation; OR, odds ratio; MD, mean difference; RARC,
robot-assisted radical cystectomy; ORC, open radical cystectomy;
LRC, laparoscopic radical cystectomy.
Discussion
BCa is a common malignancy of the urinary system.[25] ORC with pelvic lymphadenectomy is the gold standard treatment for high-risk
BCa. Minimally invasive surgical approaches have been recommended for various
surgical treatments of BCa with the hope of improving the complications and
recovery. In recent years, several studies have demonstrated the potential benefits
of LRC and RARC for the treatment of patients with BCa.[26,27] One study showed that MIRC
could shorten the length of stay and reduce the 90-day episode cost compared with
ORC, but there was no significant difference in the readmission rate between MIRC
and ORC.[28]Notably, most reports on MIRC are retrospective studies; prospective randomized
trials are limited. The RCTs included in our meta-analysis were prospective
randomized trials and more convincing. Tang K et al.[14] performed a meta-analysis to compare robotic surgery with ORC in the
treatment of BCa. However, the study included in the meta-analysis was only one RCT
and unpersuasive. Lauridsen et al.[6] also conducted a meta-analysis that included four RCTs, but the results were
not comprehensive and only included complications and health-related quality of
life. Tang JQ et al.[15] performed a meta-analysis that only focused on RARC versus ORC.Our meta-analysis included nine prospective randomized trials, and the outcomes were
comprehensive. We also performed a subgroup analysis to further compare RARC versus
ORC and LRC versus ORC. The outcomes of our meta-analysis suggest that MIRC and ORC
in the treatment of BCa were not significantly different with respect to oncologic
variables (recurrence rate and mortality) or pathologic variables (lymph node yield,
positive lymph nodes, and positive surgical margins). This indicates that MIRC is as
effective as ORC, which is considered to be the gold standard in the treatment BCa.
However, our assessment of the perioperative variables and complications suggested
that MIRC has a longer operating time, less estimated blood loss, lower blood
transfusion rate, shorter time to regular diet, shorter length of hospital stay, and
similar complication rate compared with ORC. These findings indicate that MIRC has
more advantages over ORC and is a more effective and safe surgical approach than ORC
in the treatment of BCa.Furthermore, the results of our subgroup analysis showed no statistically significant
difference in the recurrence rate, mortality, lymph node yield, positive lymph
nodes, positive surgical margins, operating time, estimated blood loss, blood
transfusion rate, time to regular diet, or length of hospital stay between RARC
versus ORC or LRC versus ORC. The data also suggested that LRC was associated with
fewer complications than ORC. However, the performance of RARC did not significantly
reduce the complications compared with ORC. Overall, the results of our
meta-analysis show that MIRC (RARC and LRC) is a safe and effective surgical
approach in the treatment of BCa.All of the trials on robotic surgery were performed with an extracorporeal approach,
which might have affected the results of our analysis. Future trials including the iROC[29] and the RAZOR[24] trials are currently recruiting patients for comparison of extracorporeal and
intracorporeal diversions in RARC. When assessing MIRC procedures, it is important
to specify the type of urinary diversion performed and whether it was performed
intracorporeally or extracorporeally. This information is essential because it may
have a major bearing on the outcome of perioperative variables such as the operation
time, length of hospital stay, blood loss, and complication rate. Clinically, when
assessing the feasibility of upcoming techniques and their oncologic outcomes, it is
important to ensure that there is appropriate follow-up. In the present analysis,
patients were followed up for BCa progression or death of any cause at 4 to 6 weeks,
then every 3 to 6 months for a minimum of 2 years after cystectomy. The serum
hemoglobin, creatinine, and albumin concentrations were measured at baseline and at
4 to 6 weeks and 3, 6, 12, 24, and 36 months postoperatively.Although this meta-analysis included only prospective RCTs and the quality of the
individual studies was conforming, there were some important limitations in our
analysis. First, the sample sizes of the subgroups were small. Additionally,
unpublished studies were excluded. These factors may have led to bias. Second, there
were significant differences in the adequacy of the randomization process and
blinding methodology. Third, the results may be measured in different ways, and the
researchers involved were different; for example, the extent of pelvic lymph node
dissection (standard or extended) was based on the patient’s condition,
institutional preference, and level of operation, which would determine the lymph
node yield. Finally, potential selection bias may have affected the homogeneity
between groups, and the relatively small sample sizes limited the statistical power
for identifying true associations. After considering the heterogeneity between
individual studies, this meta-analysis remains important for assessing the efficacy
and safety of MIRC in the treatment of BCa. We suggest that more high-quality
randomized trials with larger samples are needed to learn more about MIRC versus ORC
in the treatment of BCa.
Conclusion
This meta-analysis suggest that MIRC is a safe and effective surgical approach in the
treatment of BCa. However, large-scale multicenter randomized controlled study is
still needed to further confirm.
Authors: Seth A Cohen; Hossein S Mirheydar; J Kellogg Parsons; Kerrin L Palazzi; Michael A Liss; David C Chang; Christopher J Kane; A Karim Kader Journal: Urology Date: 2014-06-21 Impact factor: 2.649
Authors: Georgios Gakis; Jason Efstathiou; Seth P Lerner; Michael S Cookson; Kirk A Keegan; Khurshid A Guru; William U Shipley; Axel Heidenreich; Mark P Schoenberg; Arthur I Sagaloswky; Mark S Soloway; Arnulf Stenzl Journal: Eur Urol Date: 2012-08-14 Impact factor: 20.096
Authors: Parth K Modi; Brent K Hollenbeck; Mary Oerline; Alon Z Weizer; Jeffrey S Montgomery; Samuel D Kaffenberger; Andrew M Ryan; Chad Ellimoottil Journal: Urology Date: 2018-10-23 Impact factor: 2.649
Authors: T Lin; X Fan; C Zhang; K Xu; H Liu; J Zhang; C Jiang; H Huang; J Han; Y Yao; W Xie; W Dong; L Bi; J Huang Journal: Br J Cancer Date: 2014-01-09 Impact factor: 7.640
Authors: Keiran D Clement; Emily Pearce; Ahmed H Gabr; Bhavan P Rai; Abdulla Al-Ansari; Omar M Aboumarzouk Journal: World J Urol Date: 2020-07-30 Impact factor: 4.226